Drug intelligence / Profile preview

MK-1942 + donepezil

Development stage: Discontinued
Lead developer: Merck
Modality: Small Molecules
Administration: Oral

Overview

MK-1942 + donepezil is an investigational combination therapy that was being studied for the treatment of Alzheimer's disease. MK-1942 is an experimental drug developed by Merck (MSD) that was being evaluated as an adjunct to donepezil, an established cholinesterase inhibitor used in Alzheimer's treatment. Clinical trials were designed to assess safety, pharmacokinetic interactions, and potential efficacy of this combination in patients with mild to moderate Alzheimer's disease dementia who were stably treated with donepezil.

Targets

Acetylcholinesterase

Beyond the preview

Go deeper on MK-1942 + donepezil.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MK-1942 + donepezil.

Explore the full profile